Posted by Michael Wonder on 19 Apr 2023
Madrigal receives breakthrough therapy designation from FDA for resmetirom
18 April 2023 - Madrigal Pharmaceuticals today announced that resmetirom has received breakthrough therapy designation from the US FDA for the treatment of patients with NASH with liver fibrosis.
The Company also announced that the outcomes portion of the Phase 3 MAESTRO-NASH biopsy trial has completed enrollment.
